论文部分内容阅读
目的观察阿仑膦酸钠对糖尿病合并原发性骨质疏松症骨密度的影响及其安全性。方法收集在我院就诊的糖尿病合并原发性骨质疏松的门诊及住院患者共106例,所有患者在半年内予口服阿仑膦酸钠连续治疗,测定并比较治疗前后患者骨密度、血钙、血磷和疼痛评分,观察不良反应。结果与治疗前相比,患者治疗后的骨密度值明显升高,疼痛平均积分明显下降(P<0.05)。治疗前后,患者血钙和血磷浓度差异无统计学意义。在治疗过程中,无严重不良反应发生。结论阿仑膦酸钠治疗糖尿病伴骨质疏松症可增加患者骨密度,疗效显著。
Objective To observe the effect of alendronate on the bone mineral density (BMD) and its safety in diabetic patients with primary osteoporosis. Methods A total of 106 outpatients and inpatients with diabetic primary osteoporosis were enrolled in our hospital. All patients were treated with oral alendronate continuously within six months. The bone mineral density , Phosphorus and pain score, observed adverse reactions. Results Compared with those before treatment, the BMD of patients was significantly increased and the mean score of pain was significantly decreased (P <0.05). Before and after treatment, the patient’s serum calcium and phosphorus concentrations were no significant difference. In the course of treatment, no serious adverse reactions occurred. Conclusion Alendronate treatment of diabetes with osteoporosis can increase bone mineral density in patients with significant effect.